

Urogen Update

January 10, 2012 (Walnut Creek, CA). Urogen announced today that it has filed an 8K on January 10, 2012, its first SEC filing since August, 2010. The 8-K included disclosure on certain events which occurred in the Company since July 2010. As a result of this filing, Urogen's stock designation (URGP.PK) on the OTC Markets (OTC Pink) changed from "No Information" to "Limited Information". Dan Vickery, Chairman of the Company, said "as we take steps to transition back to a fully reporting company, we are looking forward to again filing all reportable events with the SEC in a timely fashion. Our next milestone will be completing audited financials and sharing these with investors in the normal fashion".

About Urogen Pharmaceuticals, Inc.

Urogen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urogen's lead program targets significant unmet medical need and major market opportunities in urology. Urogen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets interstitial cystitis / bladder pain syndrome, which affects approximately 10.5 million men and women in North America. For further information, please visit Urogen's website at <http://www.urogen.com>.

Forward-Looking Statement

This update may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urogen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urogen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urogen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

SOURCE: Urogen Pharmaceuticals, Inc.

Urogen Pharmaceuticals, Inc.
Dan Vickery, MBA, Ph.D.
Chairman
925-280-2861
<http://www.urogen.com>